Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.
29.09.2022
bit.bio named Emerging Star at European Mediscience Awards 2022
The award was presented at evening ceremony in central London.
bit.bio presents data at ISSCR
The posters demonstrate the capability of opti-ox technology to create any human cell.
bit.bio wins two awards at Cambridge Independent Science and Tech Awards
bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.
bit.bio launches Huntington’s disease human cell model
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
bit.bio appoints Kathryn Corzo as Chief Operating Officer
bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.
bit.bio signs up to race to zero as part of COP26
The pledge is part of our mission to code cells for novel cures and to be a purpose led company.
bit.bio raises $103 million in first close of Series B financing
Funding raised to accelerate and expand cell therapy pipeline.
bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate
Three world leaders in science and entrepreneurship appointed to bit.bio's Board of Directors.